Title: The Monitoring Efficacy of Neurogenic Bowel Treatment On Response (MENTOR) tool: Experiences as a non-hospital survey tool, validity in a Japanese rehab setting and preliminary results of its use in MS.

Speakers: Klaus Krogh, Masashi Nomi, Atsushi Sengoku, and Anton Emmanuel

Objectives:
1. Present and discuss the extended uses of MENTOR as a tool for evaluating treatment of neurogenic bowel dysfunction (NBD)
2. Demonstrate the validity of the MENTOR tool in an Asian rehab setting (Japan)
3. Discuss the preliminary data of MENTOR as an MS tool.

Audience: All audience levels of experience are welcome.

Target Audience: Physicians, nurses, therapists, researchers and consumers.

Prior learning or experience in dealing with persons with NBD and using the MENTOR tool would be helpful but not required.

Outline of Workshop (Total time = 90 minutes):

Speaker 1 Does the MENTOR work as a non-hospital survey tool to assess bowel care in persons with SCI? (15 minutes):
Speaker 2: Management of NBD in Japanese patients with SCI (10 minutes)
Speaker 3: Japanese validation of MENTOR (15 minutes)
Speaker 4: Preliminary results of MENTOR in a MS population in the UK (10 minutes)

All: Cases illustrating the use of MENTOR and discussion of treatment options + Q&A (30-40 minutes)


Disclosures:
The MENTOR Tool has been developed with unrestricted financial support from Coloplast A/S

Abstract:

Neurogenic Bowel Dysfunction (NBD) is an important cause of morbidity in persons with spinal cord injury (SCI). Many persons with SCI continue with their usual method for bowel care even though they consider it insufficient. This is unfortunate because new treatment modalities have been introduced during the last decades. The MENTOR is a simple tool developed to make healthcare professionals and persons with SCI aware of insufficiently treated NBD.

The first part of the workshop will present key aspects in assessment and treatment of NBD. This will be followed by results of assessment with MENTOR in a large population of people with SCI. Results will illustrate how the MENTOR can improve the awareness of insufficiently treated NBD and thereby change clinical practice.
Second results from formal translation and validation of the MENTOR in a Japanese setting will be presented. This will include the level of concordance between the MENTOR tool and clinical decision experienced clinicians specialized in NBD. Likewise, user-friendliness of the tool will be described among Japanese persons with NBD and compared to previous data from the US and Europe.
Third preliminary data and results on the use of MENTOR in MS, will be discussed to determine if its use might be expanded to more pathologies in the future.

Finally, cases of NBD will be presented and discussed with the audience. This will illustrate the practical use of the MENTOR and potential difference in evaluation and treatment of NBD across continents and cultures.